Literature DB >> 29681375

Clinical and Immunological Evaluation of Infection in Patients on Hemodialysis.

Yoshiaki Muraya1, Yoshiyuki Oozono1, Jun-Ichi Kadota1, Masanobu Miyazaki1, Atsuro Hashimoto1, Keiko Iida1, Kaoru Kawakami1, Ryo Shirai1, Mitsuo Kaku2, Hironobu Koga1, Takashi Harada3, Shigeru Kohno1, Kohei Hara1.   

Abstract

Infection is a major complication associated with increased morbidity and mortality in patients on hemodialysis. We analyzed the incidence and type of infection occurring in 4841 patients on hemodialysis between 1986 and 1993 in our hospital and 11 other hemodialysis centers. Infection was noted in 193 patients (4.98 infections/1000 patients/year). Pneumonia (n=71) and bacteremia (n=24) were the 2 most common infections, followed by tuberculosis (n=14), herpes zoster infections (n=12) and infections at the vascular access site (n=12). The most commonly isolated organism in pneumonia, bacteremia and vascular access site infections wasStaphylococcus aureus. Analysis of the prognosis of patients with pneumonia showed a mortality rate of 50% in patients greater than 60 years old, which was significantly higher than that of younger patients (6.7%,P<0.01), whereas the mortality rate in patients with bacteremia was not different between the 2 age groups (60.0% vs. 57.9%, respectively). We also analyzed changes in immunological function and nutritional status in 16 patients on hemodialysis and 21 healthy control subjects. Although the phagocytic and bactericidal activities of neutrophils and monocytes were not different between the groups, superoxide production, the percentage of natural killer cells and the degree of blastoid transformation with phytohemagglutinin stimulation were significantly lower in hemodialysis patients. Low levels of Niderman's index and serum albumin and transferrin indicated poor nutritional status in these patients. Furthermore, the degree of Niderman's index and serum albumin significantly correlated with impairment of immunological function, such as reduced blastoid transformation and the number of lymphocytes. Our results suggest that analysis of the patterns of infection in patients on hemodialysis should provide better management and that improvement of malnutrition may ameliorate impaired immunity in hemodialysis patients.
Copyright © 1996 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cellular immunity; chronic renal failure; hemodialysis; infection; neutrophil function; nutritional index

Year:  2014        PMID: 29681375     DOI: 10.1007/BF02355122

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

Review 1.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

Review 2.  Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues.

Authors:  Tatsuya Suwabe
Journal:  Clin Exp Nephrol       Date:  2020-07-22       Impact factor: 2.801

3.  Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia.

Authors:  Ping-Huai Wang; Hao-Chien Wang
Journal:  BMC Infect Dis       Date:  2016-08-08       Impact factor: 3.090

4.  A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.

Authors:  Issei Tokimatsu; Katsumi Shigemura; Tomohiro Kotaki; Hiroki Yoshikawa; Fukashi Yamamichi; Tadashi Tomo; Soichi Arakawa; Masato Fujisawa; Jun-Ichi Kadota
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.